170 related articles for article (PubMed ID: 19901090)
1. A novel class of meso-tetrakis-porphyrin derivatives exhibits potent activities against hepatitis C virus genotype 1b replicons in vitro.
Cheng Y; Tsou LK; Cai J; Aya T; Dutschman GE; Gullen EA; Grill SP; Chen AP; Lindenbach BD; Hamilton AD; Cheng YC
Antimicrob Agents Chemother; 2010 Jan; 54(1):197-206. PubMed ID: 19901090
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
[TBL] [Abstract][Full Text] [Related]
3. Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems.
Lin HM; Wang JC; Hu HS; Wu PS; Wang WH; Wu SY; Yang CC; Yeh TK; Hsu TA; Jiaang WT; Chao YS; Chern JH; Yueh A
Antimicrob Agents Chemother; 2013 Feb; 57(2):723-33. PubMed ID: 23165461
[TBL] [Abstract][Full Text] [Related]
4. A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants.
Ivanisenko NV; Mishchenko EL; Akberdin IR; Demenkov PS; Likhoshvai VA; Kozlov KN; Todorov DI; Gursky VV; Samsonova MG; Samsonov AM; Clausznitzer D; Kaderali L; Kolchanov NA; Ivanisenko VA
PLoS One; 2014; 9(3):e91502. PubMed ID: 24643004
[TBL] [Abstract][Full Text] [Related]
5. Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors.
Binder J; Tetangco S; Weinshank M; Maegley K; Lingardo L; Diehl W; Love R; Patick AK; Smith GJ
Antiviral Res; 2011 Aug; 91(2):102-11. PubMed ID: 21620899
[TBL] [Abstract][Full Text] [Related]
6. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.
Lin C; Gates CA; Rao BG; Brennan DL; Fulghum JR; Luong YP; Frantz JD; Lin K; Ma S; Wei YY; Perni RB; Kwong AD
J Biol Chem; 2005 Nov; 280(44):36784-91. PubMed ID: 16087668
[TBL] [Abstract][Full Text] [Related]
7. Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro.
Lu L; Pilot-Matias TJ; Stewart KD; Randolph JT; Pithawalla R; He W; Huang PP; Klein LL; Mo H; Molla A
Antimicrob Agents Chemother; 2004 Jun; 48(6):2260-6. PubMed ID: 15155230
[TBL] [Abstract][Full Text] [Related]
8. Discovery and characterization of substituted diphenyl heterocyclic compounds as potent and selective inhibitors of hepatitis C virus replication.
Huang P; Goff DA; Huang Q; Martinez A; Xu X; Crowder S; Issakani SD; Anderson E; Sheng N; Achacoso P; Yen A; Kinsella T; Darwish IS; Kolluri R; Hong H; Qu K; Stauffer E; Goldstein E; Singh R; Payan DG; Lu HH
Antimicrob Agents Chemother; 2008 Apr; 52(4):1419-29. PubMed ID: 18227176
[TBL] [Abstract][Full Text] [Related]
9. Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application.
Kneteman NM; Weiner AJ; O'Connell J; Collett M; Gao T; Aukerman L; Kovelsky R; Ni ZJ; Zhu Q; Hashash A; Kline J; Hsi B; Schiller D; Douglas D; Tyrrell DL; Mercer DF
Hepatology; 2006 Jun; 43(6):1346-53. PubMed ID: 16729319
[TBL] [Abstract][Full Text] [Related]
10. Antiviral interactions of an HCV polymerase inhibitor with an HCV protease inhibitor or interferon in vitro.
Koev G; Dekhtyar T; Han L; Yan P; Ng TI; Lin CT; Mo H; Molla A
Antiviral Res; 2007 Jan; 73(1):78-83. PubMed ID: 16945431
[TBL] [Abstract][Full Text] [Related]
11. Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
Qing J; Luo R; Wang Y; Nong J; Wu M; Shao Y; Tang R; Yu X; Yin Z; Sun Y
Antiviral Res; 2016 Feb; 126():43-54. PubMed ID: 26724382
[TBL] [Abstract][Full Text] [Related]
12. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons.
Lanford RE; Guerra B; Lee H; Averett DR; Pfeiffer B; Chavez D; Notvall L; Bigger C
J Virol; 2003 Jan; 77(2):1092-104. PubMed ID: 12502825
[TBL] [Abstract][Full Text] [Related]
13. PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
Lam AM; Murakami E; Espiritu C; Steuer HM; Niu C; Keilman M; Bao H; Zennou V; Bourne N; Julander JG; Morrey JD; Smee DF; Frick DN; Heck JA; Wang P; Nagarathnam D; Ross BS; Sofia MJ; Otto MJ; Furman PA
Antimicrob Agents Chemother; 2010 Aug; 54(8):3187-96. PubMed ID: 20516278
[TBL] [Abstract][Full Text] [Related]
14. Replication studies using genotype 1a subgenomic hepatitis C virus replicons.
Gu B; Gates AT; Isken O; Behrens SE; Sarisky RT
J Virol; 2003 May; 77(9):5352-9. PubMed ID: 12692237
[TBL] [Abstract][Full Text] [Related]
15. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells.
Lin K; Perni RB; Kwong AD; Lin C
Antimicrob Agents Chemother; 2006 May; 50(5):1813-22. PubMed ID: 16641454
[TBL] [Abstract][Full Text] [Related]
16. Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication.
Friborg J; Levine S; Chen C; Sheaffer AK; Chaniewski S; Voss S; Lemm JA; McPhee F
Antimicrob Agents Chemother; 2013 Mar; 57(3):1312-22. PubMed ID: 23274666
[TBL] [Abstract][Full Text] [Related]
17. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
Tsantrizos YS
Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
[TBL] [Abstract][Full Text] [Related]
18. Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins.
Massariol MJ; Zhao S; Marquis M; Thibeault D; White PW
Biochem Biophys Res Commun; 2010 Jan; 391(1):692-7. PubMed ID: 19944069
[TBL] [Abstract][Full Text] [Related]
19. In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122.
Ottosen S; Parsley TB; Yang L; Zeh K; van Doorn LJ; van der Veer E; Raney AK; Hodges MR; Patick AK
Antimicrob Agents Chemother; 2015 Jan; 59(1):599-608. PubMed ID: 25385103
[TBL] [Abstract][Full Text] [Related]
20. Resistance analysis and characterization of a thiazole analogue, BP008, as a potent hepatitis C virus NS5A inhibitor.
Lin HM; Wang JC; Hu HS; Wu PS; Yang CC; Wu CP; Pu SY; Hsu TA; Jiaang WT; Chao YS; Chern JH; Yeh TK; Yueh A
Antimicrob Agents Chemother; 2012 Jan; 56(1):44-53. PubMed ID: 22006008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]